These words are from Dr. Steve Cannon about the Covid-19 vaccines on the market and the ones soon to be released. We hope this information helps you make a well-informed decision about your personal health and safety.
“In terms of vaccine choices, there is no data available to have a preference of one vaccine formulation over another in terms of periodic paralysis. Nor is there any data that suggests any particular vaccine should be avoided in PP. The most active area that I have read about in terms of neuromuscular disease and COVID-19 vaccination is with regard to myasthenia gravis. Because MG is an autoimmune disease that can be aggravated by infection or vaccination, the monitoring of patient outcomes has been particularly vigilant. The bottom line is that on balance, as a patient with a neuromuscular disorder, it is far better to get protected by vaccination (any of the FDA-approved vaccines) than to decline vaccination.”
“Dr. Cannon is a well-known researcher for PP. He says the amount of potassium in the Pfizer vaccine is minuscule. I am not sure Moderna or Johnson and Johnson even contain any but ALL vaccines are safe for ALL PP patients. Many, many patients have been vaccinated now and all were completely safe.”
~ LindaPPA President (Moderna vaccine and I am Normokalemic)
More Information About COVID-19 Vaccines
COVID-19 Vaccines Update: FDA and CDC Leaders Address the Rare Disease Community
The National Organization for Rare Disorders (NORD), along with The ALS Association, Cystic Fibrosis Foundation and Muscular Dystrophy Association, is pleased to host a special webinar with leaders from the US Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) to discuss the COVID-19 vaccines with the rare disease community. FDA recently granted Emergency Use Authorization (EUA) for the Pfizer and Moderna COVID-19 vaccines.
*To view the webinar click here to register for on-demand video access.
Questions that will be addressed include:
- What do the EUAs of these vaccines mean for the rare disease community?
- When might other vaccines receive an EUA?
- Are there special considerations for the rare disease community with respect to the COVID-19 vaccines?
- What role does CDC play with respect to vaccines?
Additional questions from members of the rare community will be collected during the registration period and addressed in the live webinar.
This webinar is intended for patients, caregivers, advocates and the general public.